KSCC業績集 論文¶
1.
RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma: A Large-cohort Observational Study (KSCC1307)
Annals of Surgery
2.
Multicenter cohort studyto assess the association between changes on imaging and outcome afterregorafenib treatment (KSCC1603)
Oncology
3.
Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival.
Ando K, Emi Y, Miyanari N, Tsuji A, Sakai K, Sawai T, Imamura H, Mori S, Tokunaga S, Oki E, Saeki H, Kakeji Y, Akagi Y, Baba H, Maehara Y, Mori M; Kyushu Study Group of Clinical Cancer (KSCC).
Int J Clin Oncol. 2020 Mar 18. doi: 10.1007/s10147-020-01646-5. [Epub ahead of print]
PMID: 32189156
4.
Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.
Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M.
Cancer Chemother Pharmacol. 2020 Jan;85(1):217-223. doi: 10.1007/s00280-019-03991-3. Epub 2019 Nov 25.
PMID: 31768696
5.
Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials.
Hirose K, Oki E, Shimose T, Sakamoto S, Sasaki S, Jogo T, Hu Q, Tsuda Y, Ando K, Nakashima Y, Saeki H, Mori M.
Int J Clin Oncol. 2019 Jul 22. doi: 10.1007/s10147-019-01509-8. [Epub ahead of print]
PMID: 31332611 DOI: 10.1007/s10147-019-01509-8
6.
Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.
Hashimoto D, Arima K, Nakagawa S, Negoro Y, Hirata T, Hirota M, Inomata M, Fukuzawa K, Ohga T, Saeki H, Oki E, Yamashita YI, Chikamoto A, Baba H, Maehara Y.
J Gastroenterol. 2018 Dec 4. doi: 10.1007/s00535-018-01535-9. [Epub ahead of print]
PMID: 30515563
7.
Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, Narita Y, Satake H, Matsuda Y, Sonoda H, Shimokawa M, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Eur J Cancer. 2018 Dec;105:41-49. doi: 10.1016/j.ejca.2018.09.024. Epub 2018 Nov 2.
PMID: 30391779
8.
Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
Tanioka H, Miyamoto Y, Tsuji A, Asayama M, Shiraishi T, Yuki S, Kotaka M, Makiyama A, Shimokawa M, Shimose T, Masuda S, Yamaguchi T, Komatsu Y, Saeki H, Emi Y, Baba H, Oki E, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Oncology. 2018 Mar 7. doi: 10.1159/000486624. [Epub ahead of print]
PMID: 29514163
9.
Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.
Saeki H, Emi Y, Oki E, Tokunaga S, Kakeji Y, Akagi Y, Baba H, Baba E, Maehara Y; Kyushu Study group of Clinical Cancer (KSCC).
BMC Cancer. 2018 Jan 8;18(1):57. doi: 10.1186/s12885-017-3937-6.
PMID: 29310611
10.
Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
Miyamoto Y, Oki E, Emi Y, Tokunaga S, Shimokawa M, Ogata Y, Akagi Y, Sakamoto Y, Tanaka T, Saeki H, Maehara Y, Baba H
Anticancer Res. 2018 Jan;38(1):491-499
PMID: 29277814
11.
A prospective study of XELIRI plus bevacizumab as a first‑line therapy in Japanese patients with unresectable or recurrentcolorectal cancer (KSCC1101)
Ando K, Emi Y, Suenaga T, Hamanoue M, Maekawa S, Sakamoto Y, Kai S, Satake H, Shimose T, Shimokawa M, Saeki H, Oki E, Sakai K, Akagi Y, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Int J Clin Oncol. 2017 May 19. doi: 10.1007/s10147-017-1140-z. [Epub ahead of print]
PMID:28526907
12.
Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan.
Minami K, Morita M, Emi Y, Okamoto M, Tanaka E, Nagata S, Touyama T, Ohgaki K, Tanaka T, Okumura H, Suenaga T, Tokunaga S, Oki E, Kakeji Y, Akagi Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Int J Clin Oncol. 2017 Jan 18. doi: 10.1007/s10147-017-1088-z. [Epub ahead of print]
PMID: 28101757
13.
Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104).
Satake H, Iwatsuki M, Uenosono Y, Shiraishi T, Tanioka H, Saeki H, Sugimachi K, Kitagawa D, Shimokawa M, Oki E, Emi Y, Kakeji Y, Tsuji A, Akagi Y, Natsugoe S, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer.
Cancer Chemother Pharmacol. 2017 Jan;79(1):147-153. doi: 10.1007/s00280-016-3204-6.
PMID: 27942930
14.
Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes.
Nitta H, Shimose T, Emi Y, Imamura T, Ohnishi K, Kusumoto T, Yamamoto M, Fukuzawa K, Takahashi I, Higashi H, Tsuji A, Akagi Y, Oki E, Maehara Y, Baba H; Kyushu Study Group of Clinical Cancer (KSCC) ancillary study.
Med Oncol. 2016 Nov;33(11):118. doi: 10.1007/s12032-016-0834-9. Epub 2016 Sep 29.
PMID: 27688239
15.
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T, Emi Y, Oki E, Kobayashi K, Tsuji A, Shimokawa M, Tanaka T, Akagi Y, Ogata Y, Baba H, Yoshida K, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Cancer Chemother Pharmacol. 2016 Jul 28. [Epub ahead of print]
PMID:27468920
16.
Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302).
Oki E, Tokunaga S, Emi Y, Kusumoto T, Yamamoto M, Fukuzawa K, Takahashi I, Ishigami S, Tsuji A, Higashi H, Nakamura T, Saeki H, Shirabe K, Kakeji Y, Sakai K, Baba H, Nishimaki T, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer.
Gastric Cancer. 2016 Jul;19(3):968-76. doi: 10.1007/s10120-015-0530-z. Epub 2015 Aug 11.
PMID: 26260876
17.
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Ogata Y, Shimokawa M, Tanaka T, Emi Y, Oki E, Saeki H, Sadanaga N, Kusumoto T, Touyama T, Kimura M, Baba H, Akagi Y, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Int J Clin Oncol. 2016 Apr;21(2):335-43. doi: 10.1007/s10147-015-0895-3. Epub 2015 Sep 4.
PMID: 26338269
18.
Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
Takatsuki M, Tokunaga S, Uchida S, Sakoda M, Shirabe K, Beppu T, Emi Y, Oki E, Ueno S, Eguchi S, Akagi Y, Ogata Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Eur J Surg Oncol. 2016 Feb;42(2):184-9. doi: 10.1016/j.ejso.2015.11.007. Epub 2015 Nov 22.
PMID: 26683263
19.
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Miwa K, Oki E, Emi Y, Saeki H, Kusumoto T, Akagi Y, Ogata Y, Samura H, Tokunaga S, Ishikawa H, Tanaka T, Sueyoshi S, Higashi H, Matsuda H, Touyama T, Maehara Y; Kyushu Study Group of Clinical Cancer.
Int J Clin Oncol. 2016 Feb;21(1):110-7. doi: 10.1007/s10147-015-0850-3. Epub 2015 Jun 3.
PMID:26037783
20.
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y, Tsuji A, Tanioka H, Maekawa S, Kawanaka H, Kitazono M, Oki E, Emi Y, Murakami H, Ogata Y, Saeki H, Shimokawa M, Natsugoe S, Akagi Y, Baba H, Maehara Y.
Int J Clin Oncol. 2016 Jan 8. [Epub ahead of print]
PMID:26746689
21.
Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002).
Oki E, Emi Y, Miyamoto Y, Kabashima A, Higashi H, Ogata Y, Ikebe M, Saeki H, Tokunaga S, Shirabe K, Beppu T, Uchida S, Takatsuki M, Sakoda M, Eguchi S, Akagi Y, Kakeji Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1067-74. doi: 10.1245/s10434-015-4771-1. Epub 2015 Sep 3.
PMID:26334293
22.
Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).
Beppu T, Emi Y, Tokunaga S, Oki E, Shirabe K, Ueno S, Kuramoto M, Kabashima A,
Takahashi I, Samura H, Eguchi S, Akagi Y, Natsugoe S, Ogata Y, Kakeji Y, Baba H, Maehara Y; Kyushu Study group of Clinical Cancer (KSCC).
Anticancer Res. 2014 Nov;34(11):6655-62.
PMID:25368271[PubMed - indexed for MEDLINE]
23.
Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan.
Saeki H, Emi Y, Kumashiro R, Otsu H, Kawano H, Ando K, Ida S, Kimura Y, Tokunaga E, Oki E, Morita M, Shimokawa M, Maehara Y.
Surg Today. 2014 Aug;44(8):1457-64. doi: 10.1007/s00595-013-0716-0. Epub 2013 Sep 8.
PMID:24013837[PubMed - as supplied by publisher]
24.
Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K, Emi Y, Iyama KI, Beppu T, Ogata Y, Kakeji Y, Samura H, Oki E, Akagi Y, Maehara Y, Baba H; Kyusyu Study Group of Clinical Cancer (KSCC) ancillary study.
Eur J Surg Oncol. 2014 May;40(5):559-66. doi: 10.1016/j.ejso.2013.12.009. Epub 2013 Dec 20.
PMID:24388740[PubMed - as supplied by publisher]
25.
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).
Oki E, Emi Y, Akagi Y, Tokunaga S, Sadanaga N, Tanaka T, Ogata Y, Saeki H, Kakeji Y, Baba H, Nishimaki T, Natsugoe S, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer.
Oncology. 2013;84(4):233-9. doi: 10.1159/000346690. Epub 2013 Jan 31.
PMID:23392220[PubMed - indexed for MEDLINE]
26.
Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.
Emi Y, Kakeji Y, Oki E, Saeki H, Ando K, Kitazono M, Sakaguchi Y, Morita M, Samura H, Ogata Y, Akagi Y, Natsugoe S, Shirouzu K, Tokunaga S, Sirzen F, Maehara Y;
Kyushu Study Group of Clinical Cancer (KSCC).
Int J Clin Oncol. 2013 Apr;18(2):254-9. doi: 10.1007/s10147-011-0371-7. Epub 2012 Jan 13.
PMID:22240888[PubMed - indexed for MEDLINE]
27.
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience.
Ogata Y, Tokunaga S, Emi Y, Oki E, Saeki H, Shirabe K, Hasegawa H, Sadanaga N, Samura H, Fujita F, Tanaka T, Kitazono M, Yamamoto M, Morikita T, Inomata M, Kakeji Y, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer.
Surg Today. 2011 Jan;41(1):84-90. doi: 10.1007/s00595-010-4418-6. Epub 2010 Dec 30.
PMID: 21191696
28.
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience.
Baba H, Hayashi N, Emi Y, Kakeji Y, Egashira A, Oki E, Shirabe K, Toyama T, Ohga T, Yamamoto M, Hasegawa H, Kohakura F, Higashi H, Niwa K, Fujita F, Ogata Y, Kohnoe S, Inomata M, Samura H, Tokunaga S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).
Surg Today. 2011 Dec;41(12):1610-6. doi: 10.1007/s00595-011-4589-9. Epub 2011 Oct 4.
PMID:21969193[PubMed - indexed for MEDLINE]